17188-Breast Cancer-NA-457

Breast Cancer

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

  • Details

ClinicalTrials.gov ID: NCT03725059
Diagnosis Type: NA
USOR Number: 17188

  • Address

3705 West 15th Street
Plano, TX 75075
P: (972) 867-3577

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.